The short answer
Yes, a telehealth program can now plan around six compounded peptides, with a lot of conditions attached and no guarantee they last. On October 28, 2026, HHS announced an "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" (Docket HHS-OASH-2026-0496, published in the Federal Register on October 30). It says HHS "does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician" compounding BPC-157, TB-500, KPV, MOTS-c, Semax or Epitalon, provided all ten conditions are met. Emideltide (DSIP), the seventh peptide reviewed in July, is excluded.
Nothing was approved. The peptides are not on the 503A bulks list, 503B outsourcing facilities are not covered, and the notice itself says the policy "is not binding on HHS or the public." This is not legal advice; anyone launching should have counsel read the HHS documents against their own pharmacy and state.
Draft or in effect? Read the notice, then the firms
The Federal Register notice uses two words at once. It announces "the availability of a draft" policy, and two paragraphs later refers to "this interim policy," which HHS may revisit "if, among other things, a safety signal or product quality issue arises." Written comments are open for two weeks after publication, which several firms put at November 13, 2026. The policy runs until each peptide is addressed in a final rule on the 503A bulks list.
Here is where readings diverge:
| Source (date) | How it describes the status |
|---|---|
| HHS Federal Register notice (Oct 30) | "Draft" policy; also "interim policy"; not binding; comments for two weeks |
| Arnold & Porter (Nov) | Draft; says it can be withdrawn without notice and comment, and that state boards are not bound by it |
| McDermott Will & Schulte (Nov 2) | Interim policy in place until the bulks list is amended |
| AmSpa (Oct 29) | Interim policy that "now appears to be in effect"; not a blanket authorization |
| LegitScript (Nov 2) | Treats it as operative enough to change its certification review |
Our read: pharmacies are already acting on it, and an enforcement-discretion statement is by nature a statement of intent, so "in effect" and "draft" can both be true until the comment period closes and HHS says otherwise. We would not build a business that only works if the policy survives unchanged.
The six peptides and their routes
| Peptide | Routes the policy permits |
|---|---|
| BPC-157 (acetate) | Subcutaneous, intramuscular, oral, topical |
| TB-500 (acetate) | Subcutaneous or intramuscular |
| KPV (acetate) | Topical and oral |
| MOTS-c (acetate) | Subcutaneous or intramuscular |
| Semax (free base) | Intranasal only |
| Epitalon (acetate) | Subcutaneous or intramuscular, dispensed in intermittent courses |
Routes per McDermott and LegitScript. A Semax injection is outside the policy, full stop.
Tissue and Gut Recovery
The anchor group of a recovery-focused telehealth program. Most often paired together in clinical protocols.
Most discussed peptide in the recovery category. Studied for soft tissue, joint, ligament, and GI mucosa support.
Most often paired with BPC-157. Positioned around wound healing, soft tissue flexibility, and post-injury recovery.
Anti-inflammatory peptide, with patient interest concentrated around gut health and certain skin conditions.
The checklist: 10 conditions, three owners
We could not retrieve the full HHS policy text (the HHS PDF blocked our fetch), so the wording below is paraphrased from McDermott, LegitScript and BakerHostetler summaries, which agree on substance. The one phrase we quote is the label statement, which every source reproduces identically.
| # | Condition (paraphrased) | Brand | Prescriber | Pharmacy |
|---|---|---|---|---|
| 1 | The bulk substance is one of the six listed peptides | Catalog lists only the six; nothing else sold as "peptide therapy" | Prescribes only from that list | Compounds only from that list |
| 2 | Identity and route match the appendix | Product pages show the permitted route only | Orders the permitted route | Formulates only that route |
| 3 | API comes from an FDA-registered (section 510) facility with a valid certificate of analysis | Asks for proof in the pharmacy contract | None | Holds the COA per lot |
| 4 | Original manufacturer is 510-registered, cGMP-compliant, location on the COA; repackers document their own qualification | Contract clause and audit right | None | Supplier qualification file |
| 5 | Serious adverse events and quality issues reported to FDA MedWatch and the relevant states | Routes patient reports to the clinical team fast | Documents and escalates | Files the reports |
| 6 | Label reads "This is a compounded drug product. Not for resale." | Copy and packaging never contradict it | None | Prints it |
| 7 | Single active ingredient only | No stacks or combos in the catalog | One peptide per prescription line | No blends |
| 8 | Oral forms backed by documentation of adequate human oral bioavailability | Sells oral BPC-157 or KPV only if the pharmacy has it | Checks before choosing oral | Keeps the documentation |
| 9 | Only an FDA 510(k)-cleared syringe may be co-packaged | No pens, no autoinjector kits | None | Ships syringes only |
| 10 | Everything else in the FD&C Act still applies, including the patient-specific prescription and insanitary-conditions rules | Never ships without a prescription | Real, documented evaluation per patient | Normal 503A compliance |
McDermott's summary of condition 5 adds that patient labeling must explain how to report a reaction. BakerHostetler' summary does not mention that, and we could not check it against the HHS text, so treat it as likely and confirm with your pharmacy.
Most conditions are the pharmacy's. The brand's job is to never sell something the pharmacy cannot lawfully make, and to prove it chose a pharmacy that can.
What the policy does not allow
Blends. BPC-157 plus TB-500 in one vial is out. LegitScript reads the single-API condition as excluding any combination with another active ingredient. Our April program design post noted that those two are usually marketed together; under this policy they can only be two separate prescriptions, two separate products.
Pens. The only delivery device is a 510(k)-cleared syringe. LegitScript says injector pens do not qualify.
503B. Outsourcing facilities are not covered. Bulk office-stock supply from a 503B is not what this policy describes.
Approval claims. HHS says compounded drugs are not FDA-approved, and LegitScript tells merchants to review "labels, marketing, and patient communications" so nothing suggests enforcement discretion means approval. "FDA-cleared BPC-157" on a landing page is a fast way to lose certification.
Research-use sales. BakerHostetler notes products sold as research chemicals or dietary supplements are outside the policy, and FDA's August 24 warning letters to five peptide vendors rejected that defense (Holland & Knight).
The other peptides. LL-37, GHK-Cu, DiHexa, Melanotan II, PEG-MGF and emideltide are not covered. Holland & Knight expects a second advisory committee meeting on the remaining five before the end of February 2027, with no date set; our post-meeting roadmap covers how that process runs.
Why it could reverse
FDA's Center for Drug Evaluation and Research recommended against adding each of the six to the bulks list, and Arnold & Porter says the policy's appendix acknowledges that. STAT reported on October 29 that HHS acted "despite objections from FDA career scientists." The Partnership for Safe Medicines has filed a citizen petition (FDA-2026-P-13366) asking FDA not to allow this compounding through enforcement discretion. HHS reserved the right to revisit the policy on a safety signal, and an enforcement-discretion statement can be withdrawn without rulemaking.
So the risk is real and uneven. A single endotoxin cluster, like the glutathione illnesses FDA and CDC reported in August and September, could end it for one peptide or all six. We would launch a peptide line only as an addition to a program that pays its bills without it, which is the same advice our September guide gave when nothing was covered.
LegitScript, processors and ad platforms
LegitScript changed its certification review on November 2: offering one of the six "should not, by itself, prevent a merchant from achieving certification," as long as the policy's conditions are met. Peptides or formulations outside the policy still block certification. LegitScript also wrote that "advertising platforms and payment providers set their own policies," which may not move on its timeline.
We found no Google or Meta ad policy change tied to the HHS action as of November 4. Both require LegitScript for telehealth advertisers (details in our LegitScript post), but certification is the entry ticket, and a peptide ad can still be rejected. Payment underwriters will read the catalog too.
Where Turbopills fits
The conditions that touch software are the catalog, the intake and the routing. In Turbopills each product is configured on its own, so a catalog can carry BPC-157 subcutaneous and BPC-157 topical as separate single-ingredient products, with no blend SKU and no pen kit to accidentally publish. Conditional intake screens eligibility and contraindications per product before a licensed provider in the patient's state reviews the chart. That matters beyond this policy: Holland & Knight notes that a September 18 FDA warning letter questioned prescriptions generated through "preselected options on third-party telehealth platforms," so the clinician should choose the peptide, route and dose, and the checkout should not.
Pharmacy routing sends each order to an integrated pharmacy with live status. What we would ask you to verify in a demo: that peptide orders can be routed only to the 503A pharmacy you qualified, which pharmacies available to your program compound these six under the policy, whether they will show COAs and supplier files, and how a patient's adverse-event report reaches both your clinician and the pharmacy. The founder still owns the medical director, the protocols, the pharmacy choice and the LegitScript application. We are in private beta and quote per program.
FAQ
Is BPC-157 legal to prescribe now? HHS said on October 28, 2026 it does not intend to take enforcement action against 503A compounding of BPC-157 that meets ten conditions, on a valid patient-specific prescription. It is still not FDA-approved and not on the 503A bulks list, and the policy can be revised or withdrawn.
Can a 503B outsourcing facility make these peptides? No. The policy covers state-licensed pharmacies, federal facilities and licensed physicians compounding under section 503A. 503B is not covered.
Can I sell a BPC-157 and TB-500 blend? No. The policy requires a single active ingredient. Each peptide has to be its own product and its own prescription line.
Will LegitScript certify a peptide clinic now? Since November 2, offering one of the six within the policy's conditions should not by itself block certification. Other peptides, blends or out-of-scope routes still do, and certification does not guarantee approval by ad platforms or payment processors.